13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SILLAJEN RCC

    Acronym: 

    JX594-REN026

    ACTRN/NCT /ethics: 

    Ethics: 55.18

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase I Tumour Stream Kidney
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Kidney
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 1b dose escalation study of Pexa-Vec (Thyidine Kinase- deactivated vaccinia virus plus GM-CSF) in combination with REGN2810 (anti-PD-1) in patients with metastatic or unresectable renal cell carcinoma

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Not Yet Recruiting